CTAG1A
Cancer/testis antigen 1
As of the edition of 20 October 2026, CTAG1A (cancer/testis antigen 1, UniProt P78358) has 1 drug tested at it and 1 company on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P78358
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Solved structures
- 26
- Disease areas
- Cancer; Skin and connective tissue; Hormones; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Digestive system
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rasdegafusp alfa | Went quiet | Phase 2 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Total on the list | 1 |
| Company | Route |
|---|---|
| Celldex Therapeutics | Route A |
The other 0 companies at CTAG1A
In the product1 company in all; 0 are not named here, and no score is.
See the 1 companies at CTAG1A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.